Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial
暂无分享,去创建一个
K. Ozono | T. Kubota | Y. Seino | N. Namba | K. Muroya | Shunichiro Orihara | H. Kanda | M. Kanematsu | Hiroyuki Tanaka | M. Kojima
[1] Diana Athonvarangkul,et al. New Therapies for Hypophosphatemia-Related to FGF23 Excess , 2020, Calcified Tissue International.
[2] A. Schindeler,et al. Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children , 2020, Frontiers in Endocrinology.
[3] M. Brandi,et al. Congenital Conditions of Hypophosphatemia Expressed in Adults , 2020, Calcified Tissue International.
[4] A. González-Meneses López. FGF23-Related Hypophosphataemic Bone Disease , 2020, Advances in Therapy.
[5] Leire Madariaga,et al. Hypophosphataemic Rickets: Similar Phenotype of Different Diseases , 2020, Advances in Therapy.
[6] P. Arango Sancho. Complications of Phosphate and Vitamin D Treatment in X-Linked Hypophosphataemia , 2020, Advances in Therapy.
[7] R. Lachmann,et al. Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study , 2020, Quality of Life Research.
[8] A. Rothenbuhler,et al. Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH). , 2020, Metabolism: clinical and experimental.
[9] W. Högler,et al. New Developments in the Treatment of X-Linked Hypophosphataemia: Implications for Clinical Management , 2020, Pediatric Drugs.
[10] Anisha Gohil,et al. FGF23 and Associated Disorders of Phosphate Wasting. , 2019, Pediatric endocrinology reviews : PER.
[11] C. Stournaras,et al. Regulation of fibroblast growth factor 23 (FGF23) in health and disease , 2019, FEBS letters.
[12] F. Glorieux,et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial , 2019, The Lancet.
[13] L. Rejnmark,et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia , 2019, Nature Reviews Nephrology.
[14] J. S. San Martin,et al. The Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey , 2019, Journal of the Endocrine Society.
[15] J. S. San Martin,et al. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. , 2019, The lancet. Diabetes & endocrinology.
[16] O. Mäkitie,et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity , 2019, Orphanet Journal of Rare Diseases.
[17] A. Rothenbuhler,et al. X-linked hypophosphatemia: Management and treatment prospects. , 2019, Joint, bone, spine : revue du rhumatisme.
[18] H. Cheong,et al. First‐in‐Asian Phase I Study of the Anti‐Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X‐linked Hypophosphatemia , 2018, JBMR plus.
[19] K. Miyamoto,et al. Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy , 2018, Pflügers Archiv - European Journal of Physiology.
[20] J. S. San Martin,et al. Burosumab Therapy in Children with X‐Linked Hypophosphatemia , 2018, The New England journal of medicine.
[21] Yvette N. Lamb. Burosumab: First Global Approval , 2018, Drugs.
[22] F. Glorieux,et al. Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia , 2016, Bone reports.
[23] I. Endo,et al. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. , 2015, Endocrine journal.
[24] F. Glorieux,et al. Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. , 2015, The Journal of clinical endocrinology and metabolism.
[25] T. Carpenter,et al. Hypophosphatemic Rickets: Lessons from Disrupted FGF23 Control of Phosphorus Homeostasis , 2015, Current Osteoporosis Reports.
[26] M. Peacock,et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. , 2014, The Journal of clinical investigation.
[27] I. Holm,et al. A clinician's guide to X‐linked hypophosphatemia , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[28] L. Dimeglio,et al. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. , 2010, The Journal of clinical endocrinology and metabolism.
[29] T. K. Jensen,et al. Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. , 2009, European journal of endocrinology.
[30] D. Schlessinger,et al. Mutational analysis of PHEX gene in X-linked hypophosphatemia. , 1998, The Journal of clinical endocrinology and metabolism.
[31] F. Schranck,et al. X-linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children. , 1996, The Journal of clinical endocrinology and metabolism.
[32] C. Dent,et al. VITAMIN D-RESISTANT RICKETS. ANALYSIS OF TWENTY-FOUR PEDIGREES WITH HEREDITARY AND SPORADIC CASES. , 1964, The American journal of medicine.
[33] T. Carpenter. The expanding family of hypophosphatemic syndromes , 2011, Journal of Bone and Mineral Metabolism.
[34] H. Orimo,et al. [Fanconi syndrome]. , 1968, Naika. Internal medicine.